Mechanisms of Anticancer Drug Action

• 5685 · PDF Mitotic error-tolerant survival following WRN inhibition is overcome by sustained spindle checkpoint activation Sungmin Cho, Joong-Bae Ahn, Sang Joon Shin
• 5686 · PDF SF3B1 inhibition suppresses prostate cancer by disrupting ATRX splicing and inducing cell cycle arrest Linyue Li, Weijian Ding, Zhihao Nie, Congrong Jiang, Ruining Zhao, Siyuan Xia, Baotong Zhang
• 5687 · PDF Targeting KIFC1 induces anaphase catastrophe in small cell lung cancer Minemichi Toda, Natsuki Nakagawa, Masakatsu Tokunaga, Mirei Ka, Takahiro Iida, Hiroaki Ikushima, Takahiro Ando, Akiko Kunita, Kousuke Watanabe, Xi Liu, Ethan Dmitrovsky, Hidenori Kage, Masanori Kawakami
• 5688 · PDF Synthetic lethal targeting of TRIP13 and Aurora A induces mitotic DNA damage and concurrent pyroptotic-apoptotic cell death in Rb-deficient cancer cells Lacin Yapindi, Soma Ghosh, Li Shen, Lixia Diao, Jing Wang, Faye M. Johnson
• 5689 · PDF Flow-cytometric analysis of cell-cycle arrest and apoptosis induced by a novel benzopyran derivative (SK6) in MCF-7 breast cancer cells Mariappan Gurusamy, Razia Shaika, Brijesh Sharma
• 5690 · PDF Mechanisms of efficacy of endonuclease FEN1 inhibition in neuroblastoma Carla S. Sampaio, Eric Wu, Madison Cinelli, Erica Steen, Andrew Shiau, Richard Kolodner, Jean Wang, Peter E. Zage
• 5691 · PDF Per and polyfluoroalkyl substances (PFAS) promote proliferation and migration in genetically distinct kidney cancer cell lines Rakesh Kumar Arya, Mia Sand, Sahab Ram Dewala, Can Aydogdu, Gabriela M. Diaz, Christopher Weight, Riccardo Autorino, Abhishek Chakraborty, Jacob M. Knorr, Joseph M. K. Irudayaraj, Laura Bukavina
• 5692 · PDF Mechanism of antiproliferative activity of tolfenamic acid Fatima Rehman, Hesham Syed, Umesh T. Sankpal
• 5693 · PDF Synergy of a CDK4/6 inhibitor and an HDAC inhibitor in pancreatic cancer overcomes autophagy Vikas Dukhande, Shraddha Bhutkar, Anjali Yadav
• 5694 · PDF SQLE inhibitor triggers ovarian cancer apoptosis by causing ER stress Cheng Chi, Lei Sun, Mahmuda Akter, Shuang Huang
• 5695 · PDF CyTOF analysis of targeted therapy in addition to standard of care against Ewing sarcoma tumor subpopulations Kaitlyn H. Smith, Lucy Endean, Kimberly Q. McKinney, Poornima Gourabathini, Kenzie Wells, Jeffrey Huo, Erin M. Trovillion, Javier Oesterheld
• 5696 · PDF RAS(ON) multi-selective inhibitors stimulate the hydrolysis of RAS-GTP to RAS-GDP and drive synergistic combination benefit with KRAS(OFF) inhibitors in G12 mutant tumors Hiroyuki Matsubara, Alec Millner, Yu C. Yang, Jun Sun, Stephanie Change, Shelby L. Steele, Marini Thian, Miguel Sandoval, Zhican Wang, Mike Flagella, Mallika Singh, Jingjing Jiang, Jacqueline A. M. Smith, Ryan B. Corcoran, Kyle J. Seamon
• 5697 · PDF EZH2 inhibition upregulates GD2 to enhance anti-GD2 immunotherapy in Ewing sarcoma Kenzie Wells, Kimberly Q. McKinney, Kaitlyn H. Smith, Poornima Gourabathini, Jeffrey Huo, Erin M. Trovillion, Javier Oesterheld
• 5698 · PDF Exploiting MYC Oncogenic Stress for Therapeutic Benefit in Lymphoma Smriti Kanangat, James D. Phelan, Louis Staudt
• 5699 · PDF Tegavivint directly targets TBL1 to inhibit b-catenin nuclear oncogenic activity Aundrietta Duncan, Prashi Jain, Elena Ramirez, Julissa Simmons, Mahtab Youseffi, Stephen Horrigan
• 5702 An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids Daniele Mori, Javier Frias Aldeguer, Rene Overmeer, Sylvia F. Boj
• 5703 Profiling osteosarcoma convergent evolution and molecular adaptations through patient-derived organoid drug-screening Kailee A. Rutherford, Jonathan N. Levi, Summer Norris, Alice Soragni
• 5704 · PDF Preclinical studies reveal that protease-mediated payload release and immuno-oncology/immunomodulatory effects contribute to the antitumor activity of HLX43 Lixin Feng, Jijun Yuan, Wan-Jen Yang, Chenqiang Jia, Ge Song, Qingyu Wang, Jun Zhu
• 5705 · PDF Identifying androgen deprivation-induced responses in prostate cancer with single cell multiomic analysis Anni Perämäki, Iina Koivisto, Alfonso Urbanucci, Frank Claessens, Mikael Marttinen, Matti Nykter
• 5706 · PDF Modeling the influence of Tumor Treating Fields (TTFields) treatment usage time and break patterns on therapeutic outcomes Rotem Engelman, Daria Gerasimova, Talya Borkum, Eyal Dor-On, Itai Tzchori, Hila Fishman, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti, Na Tosha N. Gatson
• 5707 · PDF Mechanism of action of GEM144, a POLA1-HDAC11 dual inhibitor, in colorectal cancer models Rana Abdel-Samad, Avery Lazaro, Maura Mack, Berthe Hayar, Claudio Pisano, Nadine Darwiche
• 5708 · PDF Dual targeting of PDPK1 and mutated BRAFV600E is synthetically lethal Tejinder Pal Khaket, Chandrayee Gosh, Zhongyue Yang, Electron Kebebew

在完整检索应用中浏览本分会场 →